BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis. Richard Furie, the lead investigator of...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...
BC Extra | Jul 25, 2019
Company News

Breath takeout gives Zambon lung transplant candidate, U.S. foothold

Italian pharma Zambon is acquiring Sofinnova Partners portfolio company Breath Therapeutics for €140 million ($156 million) up front to expand its respiratory pipeline and establish a foothold in the U.S. Shareholders of Breath Therapeutics B.V....
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
BC Extra | Jun 28, 2019
Politics & Policy

‘Product hopping’ under fire in Senate bill

When Allergan withdrew Alzheimer's disease drug Namenda memantine from the market so physicians would prescribe a reformulated once-daily version with a longer patent life, the company was engaging in an anticompetitive practice, according to Sen....
BC Extra | Apr 15, 2019
Company News

Supreme Court decision signals likely end to Allergan sovereign immunity gambit

A lower court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review (IPR) will stand, as the U.S. Supreme Court rejected a petition from Allergan and the Saint...
BC Week In Review | Mar 1, 2019
Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million on Feb. 26 in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through...
BC Extra | Feb 26, 2019
Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA...
BC Week In Review | Jan 18, 2019
Company News

Tribe, Allergan appeal sovereign immunity patent case to Supreme Court

The Saint Regis Mohawk Tribe and Allergan plc (NYSE:AGN) asked the U.S. Supreme Court to review a federal court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review...
BC Extra | Jan 15, 2019
Company News

Tribe, Allergan appeal sovereign immunity patent case to Supreme Court

The Saint Regis Mohawk Tribe and Allergan plc (NYSE:AGN) asked the U.S. Supreme Court to review a federal court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review...
Items per page:
1 - 10 of 637